{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06455202",
            "orgStudyIdInfo": {
                "id": "CDX0159-13"
            },
            "secondaryIdInfos": [
                {
                    "id": "2024-513210-36-00",
                    "type": "CTIS"
                }
            ],
            "organization": {
                "fullName": "Celldex Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)",
            "officialTitle": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2)",
            "acronym": "EMBARQ-CSU2",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-phase-study-of-barzolvolimab-in-participants-with-chronic-spontaneous-urticaria-csu"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-07",
            "studyFirstSubmitQcDate": "2024-06-07",
            "studyFirstPostDateStruct": {
                "date": "2024-06-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-24",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Celldex Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.",
            "detailedDescription": "This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose.\n\nThere is a screening period of up to 4 weeks, followed by a 24-week placebo-controlled treatment period, a 28-week active treatment period where all participants receive barzolvolimab followed by a 16-week treatment free period.\n\nApproximately 915 adult participants (610 in the active arms and 305 in the placebo arm) will be randomly assigned to the treatment arms."
        },
        "conditionsModule": {
            "conditions": [
                "Chronic Spontaneous Urticaria"
            ],
            "keywords": [
                "CDX-0159",
                "barzolvolimab",
                "chronic spontaneous urticaria",
                "CSU",
                "urticaria activity score",
                "itch severity score",
                "hives severity score"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 915,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "barzolvolimab 150 mg",
                    "type": "EXPERIMENTAL",
                    "description": "barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks",
                    "interventionNames": [
                        "Biological: barzolvolimab"
                    ]
                },
                {
                    "label": "barzolvolimab 300 mg",
                    "type": "EXPERIMENTAL",
                    "description": "barzolvolimab given once as a 450 mg subcutaneous injection followed by 300 mg administered every 8 weeks for 52 weeks",
                    "interventionNames": [
                        "Biological: barzolvolimab"
                    ]
                },
                {
                    "label": "Placebo then barzolvolimab 150 mg",
                    "type": "EXPERIMENTAL",
                    "description": "Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 300 mg followed by 150 mg administered every 4 weeks for 28 weeks.",
                    "interventionNames": [
                        "Biological: barzolvolimab",
                        "Biological: Matching placebo"
                    ]
                },
                {
                    "label": "Placebo then barzolvolimab 300 mg",
                    "type": "EXPERIMENTAL",
                    "description": "Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 450 mg followed by 300 mg administered every 8 weeks for 28 weeks.",
                    "interventionNames": [
                        "Biological: barzolvolimab",
                        "Biological: Matching placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "barzolvolimab",
                    "description": "Subcutaneous Administration",
                    "armGroupLabels": [
                        "Placebo then barzolvolimab 150 mg",
                        "Placebo then barzolvolimab 300 mg",
                        "barzolvolimab 150 mg",
                        "barzolvolimab 300 mg"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "Matching placebo",
                    "description": "Matching placebo Subcutaneous Administration",
                    "armGroupLabels": [
                        "Placebo then barzolvolimab 150 mg",
                        "Placebo then barzolvolimab 300 mg"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score)",
                    "description": "Evaluate efficacy of barzolvolimab on urticaria activity as measured by urticaria activity score (UAS).\n\nThe UAS7 is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0.",
                    "timeFrame": "From Day 1 (first dose) to Day 85 (Week 12)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Mean change from baseline to Week 12 of ISS7 (Itch Severity Score)",
                    "description": "The ISS7 and HSS7 combined together make up the UAS7 scoring system to evaluate urticaria signs and symptoms. The ISS7 is the itch severity score for 7 days, the scores range from 0 to 21.",
                    "timeFrame": "From Day 1 (first dose) to Day 85 (Week 12)"
                },
                {
                    "measure": "Mean change from baseline to Week 12 of HSS7 (Hives Severity Score)",
                    "description": "The ISS7 and HSS7 combined together make up the UAS7 scoring system to evaluate urticaria signs and symptoms. The HSS7 score is the wheal/hives severity score for 7 days, the scores range from 0 to 21.",
                    "timeFrame": "From Day 1 (first dose) to Day 85 (Week 12)"
                },
                {
                    "measure": "Percentage of patients with UAS7=0 at Week 12",
                    "description": "Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12.",
                    "timeFrame": "From Day 1 (first dose) to Day 85 (Week 12)"
                },
                {
                    "measure": "Mean change from baseline in UAS7 in participants refractory to omalizumab treatment at Week 12",
                    "description": "Evaluate efficacy of barzolvolimab on urticaria activity as measured by urticaria activity score (UAS) in participants who did not respond to or did not tolerate omalizumab.\n\nThe UAS7 is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0.",
                    "timeFrame": "From Day 1 (first dose) to Day 85 (Week 12)"
                },
                {
                    "measure": "Proportion of participants with UAS7 = 0 in participants refractory to omalizumab treatment at Week 12",
                    "description": "Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12 in participants who did not respond to or did not tolerate omalizumab.",
                    "timeFrame": "From Day 1 (first dose) to Day 85 (Week 12)"
                },
                {
                    "measure": "Percentage of participants with UAS7 \u2264 6 at Week 12",
                    "description": "Proportion of participants who achieve control of their urticaria signs and symptoms (UAS7 \\</=6) at Week 12.",
                    "timeFrame": "From Day 1 (first dose) to Day 85 (Week 12)"
                },
                {
                    "measure": "Mean change from baseline in UAS7 at Week 4",
                    "description": "Evaluate efficacy of barzolvolimab on urticaria activity as measured by urticaria activity score (UAS).\n\nThe UAS7 is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0.",
                    "timeFrame": "From Day 1 (first dose) to Day 29 (Week 4)"
                },
                {
                    "measure": "Mean change from baseline in UAS7 at Week 24",
                    "description": "Evaluate efficacy of barzolvolimab on urticaria activity as measured by urticaria activity score (UAS).\n\nThe UAS7 is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42, and a minimum possible score of 0.",
                    "timeFrame": "From Day 1 (first dose) to Day 169 (Week 24)"
                },
                {
                    "measure": "Percentage of participants with UAS7 = 0 at Week 24",
                    "description": "Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 24.",
                    "timeFrame": "From Day 1 (first dose) to Day 169 (Week 24)"
                },
                {
                    "measure": "Incidence of Treatment-Emergent Adverse Events",
                    "description": "Occurrence of treatment emergent adverse events and serious adverse events during the study.",
                    "timeFrame": "From Day 1 (first dose) to Day 477 (Week 68)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Males and females, \\>/= 18 years of age.\n2. Diagnosis of chronic spontaneous urticaria (CSU) \\>/= 6 months.\n3. CSU despite the use of a stable regimen of second generation non-sedating H1-antihistamine as defined by:\n\n   1. The presence of hives for \\>/= 6 weeks at any time prior to Visit 1 despite the use of non-sedating H1-antihistamines.\n   2. Must be on a stable regimen of second generation non-sedating H1-antihistamine for \\>/= 4 weeks prior to study treatment.\n   3. UAS7 of \\>/= 16 and ISS7 of \\>/= 8 during the 7 days prior to treatment.\n4. Normal blood counts and liver function tests.\n5. Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.\n6. Willing and able to complete a daily symptom electronic diary and comply with study visits.\n7. Participants with and without prior biologic experience are eligible.\n\nKey Exclusion Criteria:\n\n1. Women who are pregnant or nursing.\n2. Chronic inducible urticaria that would confound the study endpoints.\n3. Other diseases associated with urticaria.\n4. Active pruritic skin condition in addition to CSU.\n5. Medical condition that would cause additional risk or interfere with study procedures.\n6. Known HIV, hepatitis B or hepatitis C infection.\n7. Vaccination of a live vaccine within 2 months prior to study treatment (subjects must agree to avoid live vaccinations during the study). Inactivated vaccines are allowed such as seasonal influenza injection or COVID-19 vaccine.\n8. History of anaphylaxis\n9. Prior treatment with barzolvolimab\n\nThere are additional criteria that your study doctor will review with you to confirm you are eligible for the study.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Celldex Therapeutics",
                    "role": "CONTACT",
                    "phone": "844-723-9363",
                    "email": "clinicaltrials@celldex.com"
                }
            ],
            "locations": [
                {
                    "facility": "Burke Pharmaceutical Research",
                    "status": "RECRUITING",
                    "city": "Hot Springs",
                    "state": "Arkansas",
                    "zip": "71913",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Makenzie Mixon",
                            "role": "CONTACT",
                            "email": "mmixon@burkepharmaceutical.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.5037,
                        "lon": -93.05518
                    }
                },
                {
                    "facility": "Clarity Dermatology, PLLC",
                    "status": "RECRUITING",
                    "city": "Castle Rock",
                    "state": "Colorado",
                    "zip": "80109",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mallory Hull",
                            "role": "CONTACT",
                            "email": "m.hull@prgresearch.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.37221,
                        "lon": -104.85609
                    }
                },
                {
                    "facility": "Deluxe Health Center",
                    "status": "RECRUITING",
                    "city": "Miami Lakes",
                    "state": "Florida",
                    "zip": "33014",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Fabio Mansur",
                            "role": "CONTACT",
                            "email": "fmansur@deluxehealthcenter.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.90871,
                        "lon": -80.30866
                    }
                },
                {
                    "facility": "Lane Dermatology Research - Centricity - PPDS",
                    "status": "RECRUITING",
                    "city": "Columbus",
                    "state": "Georgia",
                    "zip": "31904",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Abigail Eisold",
                            "role": "CONTACT",
                            "email": "abigail.eisold@centricityresearch.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.46098,
                        "lon": -84.98771
                    }
                },
                {
                    "facility": "Treasure Valley Medical Research",
                    "status": "RECRUITING",
                    "city": "Boise",
                    "state": "Idaho",
                    "zip": "83706",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Shellie Sackman",
                            "role": "CONTACT",
                            "email": "ssackmann@tvmedresearch.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.6135,
                        "lon": -116.20345
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000014581",
                    "term": "Urticaria"
                },
                {
                    "id": "D000080223",
                    "term": "Chronic Urticaria"
                }
            ],
            "ancestors": [
                {
                    "id": "D000017445",
                    "term": "Skin Diseases, Vascular"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000006969",
                    "term": "Hypersensitivity, Immediate"
                },
                {
                    "id": "D000006967",
                    "term": "Hypersensitivity"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000002908",
                    "term": "Chronic Disease"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14396",
                    "name": "Pruritus",
                    "relevance": "LOW"
                },
                {
                    "id": "M17330",
                    "name": "Urticaria",
                    "asFound": "Urticaria",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2129",
                    "name": "Chronic Urticaria",
                    "asFound": "Chronic Spontaneous Urticaria",
                    "relevance": "HIGH"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19714",
                    "name": "Skin Diseases, Vascular",
                    "relevance": "LOW"
                },
                {
                    "id": "M10018",
                    "name": "Hypersensitivity",
                    "relevance": "LOW"
                },
                {
                    "id": "M10020",
                    "name": "Hypersensitivity, Immediate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6147",
                    "name": "Chronic Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "asFound": "Chronic",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M9709",
                    "name": "Histamine Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M9710",
                    "name": "Histamine H1 Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M84065",
                    "name": "Trichostatin A",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                }
            ]
        }
    },
    "hasResults": false
}